ZBRK1 Activators
ZBRK1 activators encompass a range of chemical compounds that facilitate the enhancement of ZBRK1's transcriptional repression functions across various signaling pathways. The adenylate cyclase activator Forskolin, for instance, raises intracellular cAMP levels, which in turn augments PKA activity; this kinase phosphorylates transcription factors and co-activators that can work in concert with ZBRK1, promoting its repressive actions on specific gene targets. Concurrently, compounds such as Trichostatin A and 5-Azacytidine, by inhibiting histone deacetylases and DNA methyltransferases respectively, foster a chromatin environment conducive to the binding of ZBRK1 to DNA, thereby facilitating its transcriptional regulatory role. Additionally, MG132, through the inhibition of proteasomal degradation, contributes to the stabilization and accumulation of ZBRK1, potentially magnifying its nuclear presence and functional activity. Similarly, Retinoic Acid, through its nuclear receptors, can potentiate ZBRK1's gene regulatory capacity, particularly in pathways governing cell differentiation.
Further augmenting the ZBRK1 activation landscape are kinase inhibitors like SP600125, LY294002, PD98059, andSB203580, which selectively inhibit JNK, PI3K, MEK, and p38 MAPK pathways, respectively. These inhibitors may bolster ZBRK1's transcriptional repression by mitigating competing signaling pathways or stabilizing its interacting partners. AICAR, as an AMPK activator, may intensify ZBRK1's involvement in DNA damage response mechanisms, while Rapamycin's inhibition of mTOR signaling may amplify ZBRK1's tumor suppressor functions by diminishing mTOR's regulatory influence. Complementing these effects, SRT1720 activates SIRT1, a deacetylase that can modulate transcription factor activity, potentially synergizing with ZBRK1 in cellular stress responses.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels which enhance PKA activity. PKA then phosphorylates transcription factors and co-activators that synergize with ZBRK1, enhancing its transcriptional repression activities on target genes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that alters chromatin structure, increasing accessibility of transcription factors like ZBRK1 to DNA, thereby enhancing ZBRK1's DNA-binding capability and functional activity. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, reducing methylation levels and promoting a more relaxed chromatin state, which could facilitate ZBRK1 binding to its target gene promoters. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 inhibits proteasomes, thereby preventing the degradation of proteins, including ZBRK1, which could lead to an accumulation and increased functional activity of ZBRK1 in the nucleus. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid influences gene expression through its nuclear receptors. These receptors can interact with ZBRK1, enhancing its ability to regulate gene transcription related to cell differentiation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that may stabilize the proteins in the JNK pathway, which can interact with ZBRK1, leading to enhanced transcriptional repression by ZBRK1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can attenuate AKT signaling, potentially increasing the activity of transcription factors like ZBRK1 by reducing competitive signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor, which could lead to reduced ERK signaling, thus potentially enhancing the activity of ZBRK1 by shifting the transcriptional regulation balance. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could enhance ZBRK1 activity indirectly by modulating the cellular response to stress and inflammation, which involves transcriptional regulation. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, which can influence transcriptional regulation. This activation may enhance ZBRK1's role in DNA damage response and repair mechanisms. | ||||||